These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. [Alopecia areata in animal models--new insights into pathogenesis and treatment of a T cell-mediated autoimmune disorder]. Freyschmidt-Paul P; Happle R; Hoffman R J Dtsch Dermatol Ges; 2004 Apr; 2(4):260-73. PubMed ID: 16285322 [TBL] [Abstract][Full Text] [Related]
30. Immunohistologic and ultrastructural comparison of the dermal papilla and hair follicle bulb from "active" and "normal" areas of alopecia areata. Hull SM; Nutbrown M; Pepall L; Thornton MJ; Randall VA; Cunliffe WJ J Invest Dermatol; 1991 May; 96(5):673-81. PubMed ID: 1827135 [TBL] [Abstract][Full Text] [Related]
31. Alopecia areata: a review of disease pathogenesis. Rajabi F; Drake LA; Senna MM; Rezaei N Br J Dermatol; 2018 Nov; 179(5):1033-1048. PubMed ID: 29791718 [TBL] [Abstract][Full Text] [Related]
32. Renbok phenomenon and contact sensitization in a patient with alopecia universalis. Harris JE; Seykora JT; Lee RA Arch Dermatol; 2010 Apr; 146(4):422-5. PubMed ID: 20404233 [TBL] [Abstract][Full Text] [Related]
33. SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction. Gao Z; Jin YQ; Wu W Oncotarget; 2017 May; 8(20):33432-33443. PubMed ID: 28418931 [TBL] [Abstract][Full Text] [Related]
34. Dinitrochlorobenzene treatment of alopecia areata. de Prost Y; Paquez F; Touraine R Arch Dermatol; 1982 Aug; 118(8):542-5. PubMed ID: 7103522 [TBL] [Abstract][Full Text] [Related]